INBRAIN Neuroelectronics

Founded 2019
Employees 40+
Primary contact
Baldiri Reixac 48
Cluster II
08028 Barcelona
Catalonia
Spain
A spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, INBRAIN Neuroelectronics is a medical device company dedicated to developing the world's first intelligent graphene-brain interface to treat a variety of conditions. INBRAIN's less-invasive graphene electrodes take advantage of some of graphene's unique properties to enable ultra-high signal resolution at levels never seen before. The INBRAIN system's machine learning software detects therapy-specific biomarkers to deliver highly focused, adaptive neuromodulation therapy that is personalized for each patient. The company's first product is designed to trigger adaptive responses for neurological therapy for epilepsy and Parkinson's disease.
Founded 2019
Employees 40+
Primary contact
Baldiri Reixac 48
Cluster II
08028 Barcelona
Catalonia
Spain

Funding 💰

Total €15.7M
Last round 🔗 $16.8M
Series A
March 30, 2021.
Select investors Asabys Partners, Alta Life Sciences, BStartup, CDTI, TruVenturo, Vsquared Ventures, ICF Capital

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving a problem: With more than 35% of the population afflicted, the cost of brain disorders is about €800 billion per year in Europe and the USA. The cost of drugs is about 20% of this financial burden, with some of their side effects delivering additional costs. In contrast, bioelectrical implants could be the faster, safer and side-effect free alternative to conventional medicines.
  • Patented tech: The INBRAIN team has spent eight years developing a manufacturing process, which has been patented, that makes graphene the way they want it in the brain. 🔗
  • Better than Elon Musk's Neuralink?: According to INBRAIN's cofounder and CEO Carolina Aguilar, the material that Musk is currently using at Neuralink, a polymer called Pedot, is much worse than graphene as it degrades inside the brain too quickly to serve as a viable material for a brain-stimulating implant. 🔗
  • Media love: The company has been featured in a few publications, including Bloomberg, Handelsblatt, PlantaDoce, BioSpace, La Vanguardia, Neurotech Reports, and more.

Video ▶️

Quotes 💬

At Asabys, we believe strongly in the promise of dedicated ecosystems in developing treatments to transform the lives of patients everywhere. This investment shows how applied science, international talent and specialized financial support can generate truly disruptive therapies addressing significant unmet needs.
Josep Sanfeliu, Asabys Managing Partner 🔗
Led by an extraordinary team of professionals and investors with long-time expertise in the industry, INBRAIN represents a revolution in current neurological treatments, addressing a clear medical need and lowering costs for healthcare systems.
Scott Moonly, managing partner at Alta Life Sciences 🔗
Last update: January 13, 2023